Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Calpain small subunit 1 is the essential regulatory partner for calpain-1 and calpain-2, two calcium-dependent cysteine proteases. It is required for the stability and activity of these heterodimeric proteases, enabling controlled proteolysis of substrates involved in cytoskeletal remodeling and cell signaling. This subunit contains an N-terminal domain rich in glycine and a Ca-binding C-terminal domain, and its genetic variants have been implicated in myotonic dystrophy and cancer progression. CAPNS1 is crucial for embryonic development and is explored as a therapeutic target, though no approved drugs specifically modulate its function at present[1][2][3][6].
Allosteric inhibition of calpain heterodimerization (disrupting CAPNS1 interaction with large subunits); Competitive inhibition at the active site of calpain proteases (general calpain inhibitors)
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Calpain small subunit 1 (CSS1).